Today announced the presentation of interim results from the first Stage I/II trial of samalizumab pde5 inhibitors.

Alexion Pharmaceuticals reviews interim results from phase 1 trial on samalizumab antibody Alexion Pharmaceuticals, Inc. today announced the presentation of interim results from the first Stage I/II trial of samalizumab, the company’s investigational, first-in-course humanized monoclonal antibody. The ongoing trial is evaluating the basic safety, maximum tolerated dosage, pharmacokinetics, and pharmacodynamics of samalizumab in adult patients with advanced stage B-cell persistent lymphocytic leukemia or multiple myeloma pde5 inhibitors . Data shown today at the 52nd American Society of Hematology Annual Meeting and Exposition in Orlando indicate that samalizumab was well tolerated at all dosages studied, exhibited a dose-dependent pharmacokinetic and biological response, and exhibited initial evidence of anti-tumor activity.

Orphatec is normally a kept development-stage biotechnology firm with headquarters in Cologne privately, Germany. In addition, Alexion has generated a extensive study collaboration with essential MoCD experts from Orphatec to accelerate advancement of the investigational therapy.?.. Alexion acquires investigational therapy for MoCD Type A ultra-rare genetic disorder from Orphatec Alexion Pharmaceuticals, Inc. announced that it has purchased patents and property from Germany-centered Orphatec Pharmaceuticals GmbH linked to an investigational therapy for patients with molybdenum cofactor deficiency Type A, a devastating ultra-rare genetic disorder seen as a severe brain harm and rapid death in newborns.